Prescription medicine
Methotrexate Brand names: Rasuvo, Otrexup, Jylamvo, Xatmep, Trexall
Methotrexate (Rasuvo) is a prescription medicine with an FDA approval on record since 1953. FDA's NDC Directory lists it from 29 generic labelers, and pharmacies paid $0.158 per methotrexate 2.5 mg tablet in the October 7, 2026 NADAC survey; its other strengths are brand-only, $21.76 per mL (Xatmep 2.5 mg/mL oral solution).
- Generic listed
- In shortage
- Boxed warning
Check it at the source: the methotrexate FDA label on DailyMed (effective May 27, 2026, Accord Healthcare Inc.); the NDA 8085 record on Drugs@FDA; every methotrexate label on DailyMed.
Highlights of the record
FDA label of May 27, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, SEVERE ADVERSE REACTIONS,.
and RISK OF MEDICATION ERRORS Methotrexate Tablets can cause embryo-fetal toxicity, including fetal death. For non-neoplastic diseases, Methotrexate Tablets is contraindicated in pregnancy. For neoplastic diseases, advise females and males of reproductive potential to use effective contraception [see Contraindications (4), Warnings and Precautions (5.1), Use in Specific Populations (8.1 , 8.3) ]. Methotrexate tablets is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis [ Contraindications (4), Warnings and Precautions (5.2) ]. Methotrexate Tablets when inadvertently administered once daily have resulted in death [ Warnings and Precautions (5.9 )]. Serious adverse reactions, including death, have been reported with methotrexate. Closely monitor for adverse reactions of the bone marrow, gastrointestinal tract, liver, lungs, skin, and kidneys. Withhold or discontinue Methotrexate Tablets as appropriate [Warnings and Precautions ( 5.3 , 5.4 , 5.5 , 5.6 , 5.7 , 5.8) ]. WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS, SEVERE ADVERSE REACTIONS, and RISK OF MEDICATION ERRORS See full prescribing information for complete boxed warning. Methotrexate Tablets can cause embryo-fetal toxicity, including fetal death. […]
Used for
From the label: indications and usageMethotrexate tablets is a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults
Forms and strengths
- 1 g
- 2.5 mg
- 5 mg
- 7.5 mg
- 15 mg
- 2 mg/ml
- 2.5 mg/ml
- 7.5 mg/.15ml
- 10 mg/.2ml
- 10 mg/.4ml
- 12.5 mg/.4ml
- 15 mg/.4ml
Injection (solution); tablet; solution; film-coated tablet; injection (powder) (lyophilized) for solution.
On the market
- Earliest approval on file
- December 7, 1953 Methotrexate Sodium, Strides Pharma Intl; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 42 first September 5, 1979; 25 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 34 of which 29 under generic applications, 5 under brand applications, repackagers included
- Last listed patent
- June 1, 2029 Rasuvo injection; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $0.158 per tablet Methotrexate 2.5 mg tablet
- Shortage (FDA)
- 7 of 14 presentations limited or unavailable updated October 6, 2026
- Recalls by its makers (FDA)
- 8 since 2012 2 Class I among all firms' recalls; latest August 1, 2024; 2 more by firms not listed as its makers
- FAERS reports
- 489,791 through July 30, 2026
What is methotrexate used for?
From the label: indications and usageMethotrexate tablets is a dihydrofolate reductase inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis ( 1.4 ) 1.1 Neoplastic Diseases is indicated for the: Methotrexate Tablets is indicated for the: treatment […]
Conditions named in the indications of methotrexate's FDA labels, with every medicine labeled for each:
From other methotrexate labelsPsoriasis: … n regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe […]
Breast cancer: Methotrexate is used alone or in combination with other anticancer agents in the treatment of breast cancer, epidermoid cancers of the head and neck, advanced mycosis fungoides (cutaneous T cell lymphoma), and lung cancer, particularly …
FDA pharmacologic class: Folate Analog Metabolic Inhibitor.
Source: FDA drug label (Methotrexate), Accord Healthcare Inc., effective May 27, 2026 (SPL set 874c7f43-a3be-4236-89cc-24c44e3c5813), via openFDA; the full label on DailyMed
What does the patient leaflet for methotrexate say first?
The FDA-approved Medication Guide or Patient Information that comes with the medicine, in its own words.
From the patient leaflet: What is the most important information I should know about Methotrexate?Methotrexate can cause serious side effects that may be severe and lead to death, including: Harm to an unborn baby, including birth defects or death of an unborn baby. Females who can become pregnant: Your healthcare provider should do a pregnancy test before you start taking Methotrexate to see if you are pregnant. If you are being treated for a medical condition other than cancer, do not take Methotrexate if you are pregnant. See Who should not take Methotrexate? If you are taking Methotrexate to treat your cancer, you and your healthcare provider will decide if you will take Methotrexate if you are pregnant. Use effective birth control (contraception) during treatment and for 6 months after your final dose of Methotrexate. Ask your healthcare provider what forms of birth control you can use during this time. Tell your healthcare provider right away if you become pregnant or think you are pregnant during treatment with Methotrexate. Males with female partners who are able to become pregnant: Use effective birth control during treatment and for 3 months after your final dose of Methotrexate. Tell your healthcare provider right away if your female partner becomes pregnant during treatment with Methotrexate. Severe allergic reactions. Severe allergic reactions can happen with Methotrexate. Signs and symptoms of a severe allergic reaction may include: skin rash, itching and hives swelling of the face, lips, tongue, or throat dizziness trouble breathing wheezing fast heart rate feeling faint stomach-area pain vomiting or diarrhea Do not take Methotrexate if you have had a severe allergic reaction to Methotrexate in the past. Get medical help right away if you develop any of the signs or symptoms of a severe allergic reaction listed above. Decreased blood cell counts. […]
From the patient leaflet: How should I store Methotrexate tablets?Store Methotrexate tablets at 68°F to 77°F (20°C to 25°C). Keep Methotrexate tablets away from light. Keep Methotrexate and all medicines out of the reach of children.
Source: FDA drug label (Methotrexate), Accord Healthcare Inc., effective May 27, 2026 (SPL set 874c7f43-a3be-4236-89cc-24c44e3c5813), via openFDA; the full label on DailyMed
Is there a generic for methotrexate (Rasuvo)?
The FDA approved the first generic methotrexate on September 5, 1979. 42 generic applications are approved; 25 of them carry a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists methotrexate from 29 labelers under a generic (ANDA) application and from 5 brand labelers. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
The Orange Book lists 1 patent for Rasuvo injection, the last expiring on June 1, 2029; a patent listed only for Jylamvo oral solution runs to October 28, 2035. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 1953 earliest approval on file
- 1979 first generic approved
- 2029 last listed patent
- 2023 to now in shortage
- red ticks recalls
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for methotrexate (Rasuvo)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.158 per Methotrexate 2.5 mg tablet, down 4% from $0.164 on October 8, 2025. Prices per unit in the table differ many-fold by strength, form and brand, so compare like with like. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Methotrexate 2.5 mg tablet (generic)
- Xatmep 2.5 mg/mL oral solution (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Methotrexate 2.5 mg tablet | Generic | $0.158 per tablet | $4.73 | -4% |
| Methotrexate 250 mg/10 mL vial | Generic | $0.702 per mL | $7.02 per vial | -64% |
| Methotrexate 50 mg/2 mL vial | Generic | $2.49 per mL | $4.99 per vial | -0.6% |
| Rasuvo 10 mg/0.2 mL autoinj | Brand | $721.81 per mL | $144.36 per autoinj | +3% |
| Rasuvo 12.5 mg/0.25 mL autoinj | Brand | $574.87 per mL | $143.72 per autoinj | +2% |
| Rasuvo 15 mg/0.3 mL autoinj | Brand | $480.00 per mL | $144.00 per autoinj | +2% |
| Rasuvo 17.5 mg/0.35 mL autoinj | Brand | $409.93 per mL | $143.48 per autoinj | +2% |
| Rasuvo 20 mg/0.4 mL autoinj | Brand | $362.29 per mL | $144.91 per autoinj | +3% |
| Rasuvo 25 mg/0.5 mL autoinj | Brand | $289.37 per mL | $144.68 per autoinj | +3% |
| Rasuvo 7.5 mg/0.15 mL autoinj | Brand | $960.29 per mL | $144.04 per autoinj | +3% |
| Trexall 10 mg tablet | Brand | $48.14 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $1,444.06 | +9% |
| Trexall 5 mg tablet | Brand | $24.09 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $722.65 | +9% |
| Trexall 7.5 mg tablet | Brand | $36.21 per tablet many times the lowest per-tablet cost; NADAC records the price, not why | $1,086.27 | n/a |
| Xatmep 2.5 mg/mL oral solution | Brand | $21.76 per mL | n/a | n/a |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
Is methotrexate in shortage?
The FDA Drug Shortage Database lists 7 of 14 methotrexate presentations as limited or unavailable (updated October 6, 2026); the first entry was posted on March 13, 2023. 7 more presentations are on the list as available.
| Presentation | Company | Status | Updated |
|---|---|---|---|
| Methotrexate Preservative Free, Injection, 1 g (NDC 63323-122-50) | Fresenius Kabi USA, LLC | Current | October 6, 2026 |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3671-01) | Teva Pharmaceuticals USA, Inc. | Current | October 1, 2026 |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3675-01) | Teva Pharmaceuticals USA, Inc. | Current | October 1, 2026 |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 0703-3678-01) | Teva Pharmaceuticals USA, Inc. | Current | October 1, 2026 |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-30) | Accord Healthcare Inc. | Current | October 3, 2026 |
| Methotrexate Sodium Preservative Free, Injection, 25 mg/1 mL (NDC 16729-277-35) | Accord Healthcare Inc. | Current | October 3, 2026 |
| Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-124-40) | Hospira, Inc., a Pfizer Company | Current | September 22, 2026 |
| Methotrexate Sodium, Injection, 1 g/40 mL (25 mg/mL) (NDC 61703-408-25) | Hospira, Inc., a Pfizer Company | Current | September 22, 2026 |
Every methotrexate presentation in the FDA shortage database
Source: FDA Drug Shortage Database via openFDA, updated October 8, 2026
Has methotrexate been recalled?
The FDA's Enforcement Report lists 10 recalls naming methotrexate since 2012: 2 Class I (the most serious), 6 Class II, 2 Class III; 1 still ongoing. 2 of them are by firms that FDA's NDC Directory does not list as a maker of methotrexate and that hold no application for it in Drugs@FDA, such as compounding pharmacies or bulk-ingredient suppliers; the recall notice names the product recalled. A recall names products and lots, not every product of the medicine.
| Started | Class | Company | Reason |
|---|---|---|---|
| August 1, 2024 | Class III | Amneal Pharmaceuticals, LLC | Presence of Foreign Tablets: Potential presence of Fludrocortisone Acetate Tablet USP 0.1 mg within the Methotrexate 2.5 mg 100-count Bottle. |
| September 22, 2023 | Class III | West-Ward Columbus Inc | Failed Tablet/Capsule Specifications: Tablets were observed to have an unsmooth surface with two tablets demonstrating illegible tablet identification and … |
| December 6, 2021 | Class II | Edge Pharma, LLC | Lack of Assurance of Sterility |
| March 15, 2021 | Class II | Cardinal Health Inc. | CGMP Deviations: Intermittent exposure to temperature excursion during storage. |
| March 19, 2020 | Class II | Edge Pharma, LLC not a listed maker | Lack of Assurance of Sterility; the media used to conduct post-compounding sterility testing for the Methotrexate product was expired. |
| June 12, 2019 | Class II | Infusion Options, Inc. | Lack of Assurance of Sterility |
| March 18, 2015 | Class I | Mylan Institutional LLC | Presence of Particulate Matter |
| May 20, 2013 | Class I | Sandoz Incorporated | Presence of Particulate Matter: Found during examination of retention samples. |
Source: FDA Enforcement Report (drug recalls) via openFDA, through October 8, 2026
What does the methotrexate label say about other medicines?
The methotrexate label names 24 other medicines in its interaction, contraindication or warning sections. The labels of 36 other medicines name methotrexate. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Aspirin | drug interactions | Oral antibiotics (including neomycin) Antifolate drugs (e.g., dapsone, pemetrexed, pyrimethamine and sulfonamides) Oral or intravenous penicillin or sulfonamide antibiotics Aspirin and other nonsteroidal anti-inflammatory drugs Highly protein-bound drugs (e.g., oral anticoagulants, phenytoin, salicylates … |
| Azathioprine | drug interactions | Therefore, patients receiving concomitant therapy with Rasuvo and other potential hepatotoxins (e.g., azathioprine, retinoids, and sulfasalazine) should be closely monitored for possible increased risk of hepatotoxicity. |
| Chloramphenicol | drug interactions | Oral antibiotics such as tetracycline, chloramphenicol, and nonabsorbable broad spectrum antibiotics, may decrease intestinal absorption of methotrexate or interfere with the enterohepatic circulation by inhibiting bowel flora and suppressing metabolism of the drug by bacteria. |
| Cyclosporine | warnings and precautions | Malignancies malignancies can occur with methotrexate The risk of cutaneous malignancies is further increased when cyclosporine is administered to patients with psoriasis who received prior methotrexate. |
| Dapsone | drug interactions | Oral antibiotics (including neomycin) Antifolate drugs (e.g., dapsone, pemetrexed, pyrimethamine and sulfonamides) Oral or intravenous penicillin or sulfonamide antibiotics Aspirin and other nonsteroidal anti-inflammatory drugs Highly protein-bound drugs (e.g., oral anticoagulants, phenytoin, salicylates … |
| Esomeprazole | drug interactions | Case reports and published population pharmacokinetic studies suggest that concomitant use of some PPIs, such as omeprazole, esomeprazole, and pantoprazole, with methotrexate (primarily at high dose), may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to … |
| Glucarpidase | warnings and precautions | … the adverse drug reaction, and availability of alternative therapy [see Dosage and Administration ( 2.6 )]. glucarpidase in patients with toxic plasma methotrexate concentrations (> 1 micromole per liter) and delayed methotrexate clearance due to impaired renal function. |
| Hydroxychloroquine | drug interactions | Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. |
| Leucovorin | drug interactions | Preliminary animal and human studies have shown that small quantities of intravenously administered leucovorin enter the CSF primarily as 5-methyltetrahydrofolate and, in humans, remain 1 to 3 orders of magnitude lower than the usual methotrexate concentrations following intrathecal administration. |
| Mercaptopurine | drug interactions | Methotrexate increases the plasma levels of mercaptopurine. |
| Neomycin | drug interactions | Oral antibiotics (including neomycin) Antifolate drugs (e.g., dapsone, pemetrexed, pyrimethamine and sulfonamides) Oral or intravenous penicillin or sulfonamide antibiotics Aspirin and other nonsteroidal anti-inflammatory drugs Highly protein-bound drugs (e.g., oral anticoagulants, phenytoin, salicylates … |
| Nitrous oxide | drug interactions | … Hepatotoxic products Proton pump inhibitors Weak acids (e.g., salicylates) Nephrotoxic products Probenecid Nitrous Oxide Coadministration of methotrexate with nitrous oxide anesthesia potentiates the effect of methotrexate on folate-dependent metabolic pathways, which may increase the risk of severe methotrexate … |
| Omeprazole | drug interactions | Case reports and published population pharmacokinetic studies suggest that concomitant use of some PPIs, such as omeprazole, esomeprazole, and pantoprazole, with methotrexate (primarily at high dose), may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to … |
| Pantoprazole | drug interactions | Case reports and published population pharmacokinetic studies suggest that concomitant use of some PPIs, such as omeprazole, esomeprazole, and pantoprazole, with methotrexate (primarily at high dose), may elevate and prolong serum levels of methotrexate and/or its metabolite hydroxymethotrexate, possibly leading to … |
Every other medicine the methotrexate label names
| Medicine named | Section | What the label says |
|---|---|---|
| Pemetrexed | drug interactions | Oral antibiotics (including neomycin) Antifolate drugs (e.g., dapsone, pemetrexed, pyrimethamine and sulfonamides) Oral or intravenous penicillin or sulfonamide antibiotics Aspirin and other … |
| Penicillamine | drug interactions | Combined use of methotrexate with gold, penicillamine, hydroxychloroquine, sulfasalazine, or cytotoxic agents, has not been studied and may increase the incidence of adverse effects. |
| Phenytoin | drug interactions | … anti-inflammatory drugs Highly protein-bound drugs (e.g., oral anticoagulants, phenytoin, salicylates, sulfonamides, sulfonylureas, and tetracyclines) Hepatotoxic products Proton pump inhibitors Weak … |
| Probenecid | drug interactions | … pump inhibitors Weak acids (e.g., salicylates) Nephrotoxic products Probenecid Nitrous Oxide Coadministration of methotrexate with nitrous oxide anesthesia potentiates the effect of methotrexate on … |
| Pyrimethamine | drug interactions | Oral antibiotics (including neomycin) Antifolate drugs (e.g., dapsone, pemetrexed, pyrimethamine and sulfonamides) Oral or intravenous penicillin or sulfonamide antibiotics Aspirin and other … |
| Ranitidine | drug interactions | … PPIs, but was not observed when methotrexate was co-administered with ranitidine. |
| Sulfamethoxazole and trimethoprim | drug interactions | Trimethoprim/sulfamethoxazole has been reported rarely to increase bone marrow suppression in patients receiving methotrexate, probably by decreased tubular secretion and/or an additive antifolate … |
| Sulfasalazine | drug interactions | Therefore, patients receiving concomitant therapy with Rasuvo and other potential hepatotoxins (e.g., azathioprine, retinoids, and sulfasalazine) should be closely monitored for possible increased … |
| Tetracycline | drug interactions | Oral antibiotics such as tetracycline, chloramphenicol, and nonabsorbable broad spectrum antibiotics, may decrease intestinal absorption of methotrexate or interfere with the enterohepatic … |
| Theophylline | drug interactions | Methotrexate may decrease the clearance of theophylline; theophylline levels should be monitored when used concurrently with Rasuvo. |
Other labels that name methotrexate
- Acitretin
- Adalimumab
- Belimumab
- Benazepril and hydrochlorothiazide
- Candesartan and hydrochlorothiazide
- Celecoxib
- Certolizumab
- Ciprofloxacin
- Daunorubicin
- Delgocitinib
- Dexlansoprazole
- Dichlorphenamide
- Diclofenac
- Diflunisal
- Divalproex
- Drospirenone and ethinyl estradiol and levomefolate
- Eltrombopag
- Etanercept
- Etodolac
- Fenoprofen
- Folic acid
- Foscarnet
- Furosemide
- Golimumab
- Ibuprofen
- Indomethacin
- Infliximab
- Ketoprofen
- Ketorolac
- Lansoprazole
- Leflunomide
- Lomitapide
- Meclofenamate
- Mefenamic acid
- Meloxicam
- Multiple vitamins
- Nabumetone
- Naproxen
- Natalizumab
- Nitisinone
- Oxaprozin
- Pegloticase
- Piperacillin and tazobactam
- Piroxicam
- Pivmecillinam
- Pretomanid
- Rabeprazole
- Rolapitant
- Salicylic acid
- Sapropterin
- Sepiapterin
- Sofosbuvir and velpatasvir and voxilaprevir
- Stiripentol
- Sulindac
- Tafamidis
- Teriflunomide
- Voriconazole
Source: FDA drug label (Methotrexate), Accord Healthcare Inc., effective May 27, 2026 (SPL set 874c7f43-a3be-4236-89cc-24c44e3c5813), via openFDA; the full label on DailyMed
What do FAERS reports show for methotrexate?
The FDA Adverse Event Reporting System holds 489,791 reports that list methotrexate among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 37,720 are coded as a death and 133,303 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as methotrexate?
9 other medicines are given the same way (oral) and in the same FDA class as methotrexate or labeled mainly for the same use (rheumatoid arthritis), the same class first. Rheumatoid arthritis lists all 46 medicines labeled for it, by any route. The first 8 are below. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Indomethacin | Rheumatoid arthritis | 25 labelers | $0.210 per capsule 75 mg capsule | No current entry |
| Hydroxychloroquine | Rheumatoid arthritis | 28 labelers | $0.149 per tablet 200 mg tablet | A presentation being discontinued |
| Tofacitinib | Rheumatoid arthritis | 24 labelers | $0.573 per tablet 5 mg tablet | No current entry |
| Leflunomide | Rheumatoid arthritis | 16 labelers | $0.324 per tablet 10 mg tablet | A presentation being discontinued |
| Penicillamine | Rheumatoid arthritis | 9 labelers | n/a | No current entry |
| Baricitinib | Rheumatoid arthritis | none listed | $92.54 per tablet 2 mg tablet | No current entry |
| Flurbiprofen | Rheumatoid arthritis | 3 labelers | $3.17 per tablet 100 mg tablet | No current entry |
| Upadacitinib | Rheumatoid arthritis | none listed | $229.31 per tablet 15 mg tablet | No current entry |
Every medicine labeled for the same conditions as methotrexate
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
How does methotrexate compare with medicines for the same use?
11 side-by-side pages set methotrexate beside a medicine whose label shares a use: approvals, generics, pharmacy cost, warnings and supply.
What next?
- Alternatives to methotrexate
- 9 medicines for the same use
- Other folate analog metabolic inhibitors
- the pharmacologic class, with prices and generics
- Methotrexate side effects
- the label's list beside FAERS reports
- Methotrexate shortage record
- every presentation, company and date
- Check an interaction
- what two or more labels say about each other